A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
Sarcoma, Kaposi, HIV Infections
About this trial
This is an interventional treatment trial for Sarcoma, Kaposi focused on measuring Interferon Alfa-2a, Sarcoma, Kaposi, Dose-Response Relationship, Drug, Drug Evaluation, Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, Zidovudine, Interferon Type I
Eligibility Criteria
Inclusion Criteria Patient must have a histologically confirmed diagnosis of Kaposi's sarcoma. Positive antibody to HIV confirmed by ELISA or Western blot on the same serum. Exclusion Criteria Active drug or alcohol abuse. Co-existing Condition: Patients with the following complications are excluded: Active opportunistic infections requiring ongoing therapy. Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study. Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia. Concurrent neoplasms other than basal cell carcinoma of skin. Known sensitivity to polymycin or neomycin. Patients with the following complications are excluded: Active opportunistic infections requiring ongoing therapy. Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study. Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia. Concurrent neoplasms other than basal cell carcinoma of skin. Known sensitivity to polymycin or neomycin. Prior Medication: Excluded: Any prior zidovudine (AZT) or interferon alpha protocol participation. Excluded within 30 days of study entry: Immunomodulating agents. Other drugs that can cause neutropenia or significant nephrotoxicity, or systemic anti-infectives. Excluded within 90 days of study entry: Antiretroviral agents. Treatment of Pneumocystis carinii pneumonia (PCP). Prior Treatment: Excluded within 30 days of study entry: Radiation therapy.
Sites / Locations
- Mem Sloan - Kettering Cancer Ctr